Form 4: Dyne Therapeutics Officer Sells Shares for Tax Withholding

Dyne Therapeutics Chief Medical Officer Douglas Kerr sold 1,564 shares of common stock for $18.36 per share to cover tax withholding obligations upon the vesting of restricted stock units.

Summary

• Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc., reported a transaction on May 13, 2026.
• The transaction involved the sale of 1,564 shares of common stock at a weighted average price of $18.36 per share.
• These shares were sold to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) granted on February 12, 2026.
• The sale was executed under a pre-arranged contract consistent with Rule 10b5-1(c) to ensure an affirmative defense against insider trading allegations.
• Following this transaction, Kerr beneficially owns 170,042 shares, which includes 148,313 unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a sale of stock by an executive, it is clearly for tax withholding purposes under a pre-established plan, mitigating concerns about insider confidence.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, indicating adherence to compliance and governance standards for executive stock transactions.
• The sale was automatic and intended to cover tax obligations, not a discretionary sale of stock by management.
• The reporting person retains a significant number of shares (170,042) and unvested RSUs, suggesting continued commitment to the company.

Negatives

• A portion of the executive's equity was sold, which could be perceived negatively by the market, although it was for tax purposes.

Risks

• The sale of shares by a key executive, even if for tax purposes, could be misinterpreted by the market as a lack of confidence in the company's future stock performance.
• The weighted average sale price was $18.36, and the filing notes sales occurred within a range of $18.20 to $18.41, indicating the price at which these shares were liquidated.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a past transaction.

Management Comments

• The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding are common and generally not indicative of negative sentiment, especially when conducted under a Rule 10b5-1 plan. However, the volume and timing relative to other insider activities can be a factor in market perception.

Stakeholder Impact

• Shareholders: The sale is for tax withholding and executed under a 10b5-1 plan, so it is unlikely to have a significant negative impact on shareholder sentiment, though any insider sale can be scrutinized.
• Employees: The transaction relates to executive compensation and tax obligations, with no direct impact on other employees.
• Management: Demonstrates adherence to compliance protocols for executive stock transactions.

Next Steps

• The reporting person will continue to hold their remaining beneficial ownership of Dyne Therapeutics stock.
• The company will continue to operate under its existing business strategy.

Key Dates

Keywords

Dyne Therapeutics, DYN, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting, Rule 10b5-1, Douglas Kerr, Chief Medical Officer